Canaan Partners

Founded in 2015 by Dr. Robert Schoelkopf, Quantum Circuits develops and manufactures quantum computers based on superconducting devices. The company focuses on creating full-stack quantum computers designed for efficient scaling, with a pioneering approach to error detection and correction.

Normunity is a biotechnology company that develops precision immuno‑oncology medicines, termed immune normalizers, designed to restore the body’s natural immune response against cancer. Leveraging a partnership with Dr. Lieping Chen’s laboratory at Yale School of Medicine, the company focuses on newly discovered mechanisms of immune disruption, such as the exclusion of T‑cells from immune‑sensitive tumors and other barriers to normal immune function. Its pipeline includes programs targeting these mechanisms to enable clinicians to treat cancer by reactivating the patient’s own immunity. Normunity operates from offices in Boston, Massachusetts, and West Haven, Connecticut.

Rallybio is a clinical-stage biopharmaceutical company focused on developing therapies for severe and rare diseases. Its programs cover hematology, immuno-inflammation, maternal-fetal health and metabolic disorders, with a lead candidate aimed at preventing fetal and neonatal alloimmune thrombocytopenia, a life-threatening condition that can cause bleeding in fetuses and newborns. Founded in 2018 and based in New Haven, Connecticut, Rallybio develops therapies across antibodies, small molecules and engineered proteins to address unmet needs in rare diseases. Guided by experienced biopharma leadership, the company emphasizes translating biology into transformative therapies for underserved patients.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Founded in 2015 by Dr. Robert Schoelkopf, Quantum Circuits develops and manufactures quantum computers based on superconducting devices. The company focuses on creating full-stack quantum computers designed for efficient scaling, with a pioneering approach to error detection and correction.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company based in Princeton, New Jersey, with additional offices in Cheshire, Connecticut, and Estero, Florida, as well as a subsidiary in Toronto, Canada. The company specializes in the development and commercialization of oncology therapies, notably Myocet™, a liposome-encapsulated doxorubicin-citrate complex designed to reduce cardiotoxicity. Sopherion holds an exclusive licensing agreement with Cephalon, Inc. for Myocet™ in the United States and Canada. The firm is currently conducting a Phase III global trial to evaluate Myocet™ in combination with Herceptin® and Taxol for treating invasive, metastatic breast cancer. This trial, which aims to recruit 363 patients across twelve countries, builds on promising Phase II results that demonstrated a 96% response rate and a median progression-free survival of two and a half years. Myocet™ is already registered for use in Canada and Europe in combination with cyclophosphamide for similar indications. Sopherion is also exploring additional oncology agents through its Minicell Peptide Display screening technologies.

Spine Wave, Inc. is a medical device company that specializes in the development and marketing of innovative solutions for spinal disorders. Founded in 2001 and based in Shelton, Connecticut, the company offers a diverse range of products including expandable PEEK spacers, interbody devices for posterior surgery, and lateral stabilization systems. Its offerings also encompass the GraftMag Graft Delivery System for large bone graft delivery, fixation products for treating thoracolumbar spine conditions, and anterior cervical plate systems for spinal fusion. Spine Wave prioritizes a surgeon-driven product development approach, enabling it to create a differentiated portfolio of less invasive and efficient surgical solutions aimed at restoring spinal function and improving patients' quality of life. The company's products are distributed through various channels, ensuring wide accessibility for spine surgeons and their patients.

Tallan is a Hartford-based technology services firm with over three decades of experience in custom application development and data management. The company delivers software development, design, and infrastructure architecture services, and offers a bug tracking database for managing defects. Its expertise spans portals, collaboration, business intelligence, application integration, mobile platforms, user experience, e‑commerce, web development, government solutions, cloud services, and IT strategy. Tallan is a Microsoft National Solution Provider and holds multiple Gold Competencies in Microsoft technologies.